File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer

TitlePPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer
Authors
Issue Date2019
Citation
Cancer Discovery, 2019, v. 9, n. 2, p. 220-229 How to Cite?
AbstractClinical trials repurposing lysosomotropic chloroquine (CQ) derivatives as autophagy inhibitors in cancer demonstrate encouraging results, but the underlying mechanism of action remains unknown. Here, we report a novel dimeric CQ (DC661) capable of deacidifying the lysosome and inhibiting autophagy significantly better than hydroxychloroquine (HCQ). Using an in situ photoaffinity pulldown strategy, we identified palmitoyl-protein thioesterase 1 (PPT1) as a molecular target shared across monomeric and dimeric CQ derivatives. HCQ and Lys05 also bound to and inhibited PPT1 activity, but only DC661 maintained activity in acidic media. Knockout of PPT1 in cancer cells using CRISPR/Cas9 editing abrogates autophagy modulation and cytotoxicity of CQ derivatives, and results in significant impairment of tumor growth similar to that observed with DC661. Elevated expression of PPT1 in tumors correlates with poor survival in patients in a variety of cancers. Thus, PPT1 represents a new target in cancer that can be inhibited with CQ derivatives. Significance: This study identifies PPT1 as the previously unknown lysosomal molecular target of monomeric and dimeric CQ derivatives. Genetic suppression of PPT1 impairs tumor growth, and PPT1 levels are elevated in cancer and associated with poor survival. These findings provide a strong rationale for targeting PPT1 in cancer.
Persistent Identifierhttp://hdl.handle.net/10722/318754
ISSN
2023 Impact Factor: 29.7
2023 SCImago Journal Rankings: 7.533
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorRebecca, Vito W.-
dc.contributor.authorNicastri, Michael C.-
dc.contributor.authorFennelly, Colin-
dc.contributor.authorChude, Cynthia I.-
dc.contributor.authorBarber-Rotenberg, Julie S.-
dc.contributor.authorRonghe, Amruta-
dc.contributor.authorMcAfee, Quentin-
dc.contributor.authorMcLaughlin, Noel P.-
dc.contributor.authorZhang, Gao-
dc.contributor.authorGoldman, Aaron R.-
dc.contributor.authorOjha, Rani-
dc.contributor.authorPiao, Shengfu-
dc.contributor.authorNoguera-Ortega, Estela-
dc.contributor.authorMartorella, Alessandra-
dc.contributor.authorAlicea, Gretchen M.-
dc.contributor.authorLee, Jennifer J.-
dc.contributor.authorSchuchter, Lynn M.-
dc.contributor.authorXu, Xiaowei-
dc.contributor.authorHerlyn, Meenhard-
dc.contributor.authorMarmorstein, Ronen-
dc.contributor.authorGimotty, Phyllis A.-
dc.contributor.authorSpeicher, David W.-
dc.contributor.authorWinkler, Jeffrey D.-
dc.contributor.authorAmaravadi, Ravi K.-
dc.date.accessioned2022-10-11T12:24:29Z-
dc.date.available2022-10-11T12:24:29Z-
dc.date.issued2019-
dc.identifier.citationCancer Discovery, 2019, v. 9, n. 2, p. 220-229-
dc.identifier.issn2159-8274-
dc.identifier.urihttp://hdl.handle.net/10722/318754-
dc.description.abstractClinical trials repurposing lysosomotropic chloroquine (CQ) derivatives as autophagy inhibitors in cancer demonstrate encouraging results, but the underlying mechanism of action remains unknown. Here, we report a novel dimeric CQ (DC661) capable of deacidifying the lysosome and inhibiting autophagy significantly better than hydroxychloroquine (HCQ). Using an in situ photoaffinity pulldown strategy, we identified palmitoyl-protein thioesterase 1 (PPT1) as a molecular target shared across monomeric and dimeric CQ derivatives. HCQ and Lys05 also bound to and inhibited PPT1 activity, but only DC661 maintained activity in acidic media. Knockout of PPT1 in cancer cells using CRISPR/Cas9 editing abrogates autophagy modulation and cytotoxicity of CQ derivatives, and results in significant impairment of tumor growth similar to that observed with DC661. Elevated expression of PPT1 in tumors correlates with poor survival in patients in a variety of cancers. Thus, PPT1 represents a new target in cancer that can be inhibited with CQ derivatives. Significance: This study identifies PPT1 as the previously unknown lysosomal molecular target of monomeric and dimeric CQ derivatives. Genetic suppression of PPT1 impairs tumor growth, and PPT1 levels are elevated in cancer and associated with poor survival. These findings provide a strong rationale for targeting PPT1 in cancer.-
dc.languageeng-
dc.relation.ispartofCancer Discovery-
dc.titlePPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1158/2159-8290.CD-18-0706-
dc.identifier.pmid30425037-
dc.identifier.scopuseid_2-s2.0-85061231521-
dc.identifier.volume9-
dc.identifier.issue2-
dc.identifier.spage220-
dc.identifier.epage229-
dc.identifier.eissn2159-8290-
dc.identifier.isiWOS:000458154500011-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats